Lenalidomide Eugia (Lenalidomide)

The drug binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding changes the complex’s target profile, leading to the degradation of transcription factors Ikaros and Aiolos. The resulting anti‑angiogenic, immunomodulatory, and anti‑proliferative actions suppress malignant blood‑cell growth.

The specific dose and schedule of Lenalidomide Eugia are determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function and other individual factors. Healthcare professionals should follow the latest clinical guidelines and product labeling when prescribing.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential must use effective contraception. The safety of Lenalidomide during breastfeeding has not been established, and nursing is generally discouraged.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug (IMiD) class, offering a distinct mechanism from proteasome inhibitors or monoclonal antibodies. It is often combined with dexamethasone or used after other regimens. Compared with older agents, Lenalidomide provides oral administration and a different side‑effect profile, but choice of therapy depends on individual patient factors and prior treatment history.

Lenalidomide Eugia tablets should be stored at room temperature, below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the package is tightly closed to maintain stability.

The medication is taken orally, usually once daily, with or without food as directed by the prescriber. Patients should swallow the tablet whole with water and follow any specific timing instructions provided by their healthcare professional.

Serious risks include venous thromboembolism, severe neutropenia or thrombocytopenia, secondary primary malignancies, and liver toxicity. Patients should be monitored closely for signs of blood clots, infections, abnormal bleeding, and liver function changes throughout treatment.

Lenalidomide is contraindicated in pregnant women, individuals with known hypersensitivity to the drug or its excipients, and patients with severe renal impairment unless dose‑adjusted. It should also be avoided in patients receiving live vaccines due to the risk of infection.